Core Insights - Hologic's Skeletal Health division has shown significant growth, with sales increasing by 62.1% in Q3 of fiscal 2025 due to the ramp-up of Horizon DXA systems [1][9] - The company will discontinue the Fluoroscan Insight FD mini C-arm by September 30, 2025, due to its low gross margin and limited growth potential [2][9] - Hologic has revised its 2025 revenue guidance to a range of $4.081 billion to $4.091 billion, supported by strong Q3 performance and reduced tariff impacts [3][9] Hologic's Business Performance - The Diagnostics business is expected to benefit from strong underlying growth drivers, including BV and CV/TV molecular diagnostic assays [3] - Breast Health is anticipated to show modest growth in Q4, while Surgical revenues are expected to be strong due to favorable year-over-year comparisons [3] - Skeletal Health is projected to experience outsized growth in Q4, competing against a full quarter of DXA stop-ship from the previous year [3][4] Market Position and Competitors - Hologic's stock has increased by 11.2% over the past six months, contrasting with a 9.4% decline in the industry [7] - GE Healthcare has introduced the Voluson Performance series in women's health ultrasound, enhancing its portfolio with AI and automation [5] - Becton, Dickinson & Company has partnered with Henry Ford Health for pharmacy automation and has placed its 1,000th BD Rhapsody System at a UK hospital [6]